StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report issued on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Evogene Trading Down 1.3 %
Shares of EVGN opened at $1.55 on Monday. The firm has a market cap of $8.32 million, a P/E ratio of -0.35 and a beta of 1.30. The company’s 50-day moving average price is $1.63 and its 200 day moving average price is $3.04. Evogene has a 12-month low of $1.20 and a 12-month high of $10.40.
Institutional Investors Weigh In On Evogene
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
See Also
- Five stocks we like better than Evogene
- Best Aerospace Stocks Investing
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What Investors Need to Know About Upcoming IPOs
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What is the Dogs of the Dow Strategy? Overview and Examples
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
